PeterLabs Holdings (0171) Fair Value & Analysis
Healthcare · MY · Market cap 63.3M MYR
Fair value as of: Jul 17, 2026
From 24 valuation models · updated 24 days ago
A solid business, but screening 23% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (0.2300 MYR). The favourable scenario is already priced in.
- Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range 0.1618 MYR – 0.4500 MYR · fair‑value band 0.1500 MYR – 0.2300 MYR · the 0.2350 MYR price screens above the 0.1800 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.
Analysis
PeterLabs Holdings (0171) currently trades at 0.2350 MYR, while our model-based Fair Value estimate is 0.1800 MYR, implying the stock looks roughly 23.4% overvalued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, PeterLabs Holdings generated revenue of 132M MYR at a net margin of -0.3%. Revenue declined 11.5% year over year. It earns a return on equity of 224.9%. Net debt stands at 3.3M MYR. Fundamentals as of Jul 17, 2026
Our scenario range runs from 0.1500 MYR (bear case) to 0.2300 MYR (bull case); at 0.2350 MYR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 48% below its 52-week high and 47% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -23%, 0171 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (0.2600 MYR) versus Dividend Discount (0.0400 MYR). Highest evidence: Growth DCF (80).
Notify me when 0171 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 62 · Market factors (momentum, volatility) 34
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PeterLabs Holdings Berhad, an investment holding company, engages in manufacturing, distribution, trading, and export of animal health and nutrition products in Malaysia and internationally. The company operates through three segments: Manufacturing, Trading, and Others.
Full company description
PeterLabs Holdings Berhad, an investment holding company, engages in manufacturing, distribution, trading, and export of animal health and nutrition products in Malaysia and internationally. The company operates through three segments: Manufacturing, Trading, and Others. It offers biosecurity products and disinfectants, compound feed supplements, feed additives, nutritional premixes, pharmaceuticals, and water-soluble supplements. The company also engages in the distribution of consumer goods, including home care, oral care, baby care, and feminine care products, as well as grain products, and processed foods and beverage products to retailers, such as supermarkets, mini markets, sundry shops, convenience stores, pharmacies, petrol kiosks, Chinese medical halls, and hardware stores. The company was founded in 2002 and is headquartered in Nilai, Malaysia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
PeterLabs Holdings reported revenue of 242M MYR in FY2024 versus 80.0M MYR in FY2020, a compound +31.9%/yr. Reported net income was 2.3M MYR in FY2024, compounding −12.4%/yr from FY2020.
0171 screens 23% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 622 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare PeterLabs Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PeterLabs Holdings (0171) overvalued or undervalued?
What is the fair value of 0171?
What is the quality score of 0171?
What is the revenue of PeterLabs Holdings (0171)?
What is the net profit margin of 0171?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PeterLabs Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.